» Articles » PMID: 34059694

High Glucose Induced C-Met Activation Promotes Aggressive Phenotype and Regulates Expression of Glucose Metabolism Genes in HCC Cells

Overview
Journal Sci Rep
Specialty Science
Date 2021 Jun 1
PMID 34059694
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is strongly associated with metabolic dysregulations/deregulations and hyperglycemia is a common metabolic disturbance in metabolic diseases. Hyperglycemia is defined to promote epithelial to mesenchymal transition (EMT) of cancer cells in various cancers but its molecular contribution to HCC progression and aggressiveness is relatively unclear. In this study, we analyzed the molecular mechanisms behind the hyperglycemia-induced EMT in HCC cell lines. Here, we report that high glucose promotes EMT through activating c-Met receptor tyrosine kinase via promoting its ligand-independent homodimerization. c-Met activation is critical for high glucose induced acquisition of mesenchymal phenotype, survival under high glucose stress and reprogramming of cellular metabolism by modulating glucose metabolism gene expression to promote aggressiveness in HCC cells. The crucial role of c-Met in high glucose induced EMT and aggressiveness may be the potential link between metabolic syndrome-related hepatocarcinogenesis and/or HCC progression. Considering c-Met inhibition in hyperglycemic patients would be an important complementary strategy for therapy that favors sensitization of HCC cells to therapeutics.

Citing Articles

High glucose facilitates hepatocellular carcinoma cell proliferation and invasion via WTAP-mediated HK2 mRNA stability.

Niu Y, Jia S, Xiao X, Tu K, Liu Q Mol Cell Biochem. 2025; .

PMID: 40032749 DOI: 10.1007/s11010-025-05235-w.


Metabolic reprogramming of glucose: the metabolic basis for the occurrence and development of hepatocellular carcinoma.

Wang K, Li X, Guo S, Chen J, Lv Y, Guo Z Front Oncol. 2025; 15:1545086.

PMID: 39980550 PMC: 11839411. DOI: 10.3389/fonc.2025.1545086.


CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges.

Zhou Y, Wei S, Xu M, Wu X, Dou W, Li H Front Immunol. 2024; 15:1489649.

PMID: 39569202 PMC: 11576447. DOI: 10.3389/fimmu.2024.1489649.


Metabolic reprogramming in hepatocellular carcinoma: a bibliometric and visualized study from 2011 to 2023.

Li X, Zhou L, Xu X, Liu X, Wu W, Feng Q Front Pharmacol. 2024; 15:1392241.

PMID: 39086383 PMC: 11289777. DOI: 10.3389/fphar.2024.1392241.


The MET Family of Receptor Tyrosine Kinases Promotes a Shift to Pro-Tumor Metabolism.

Davis J, Waltz S Genes (Basel). 2024; 15(7).

PMID: 39062731 PMC: 11275592. DOI: 10.3390/genes15070953.


References
1.
Lopez R, Arumugam A, Joseph R, Monga K, Boopalan T, Agullo P . Hyperglycemia enhances the proliferation of non-tumorigenic and malignant mammary epithelial cells through increased leptin/IGF1R signaling and activation of AKT/mTOR. PLoS One. 2013; 8(11):e79708. PMC: 3832533. DOI: 10.1371/journal.pone.0079708. View

2.
Garcia-Jimenez C, Gutierrez-Salmeron M, Chocarro-Calvo A, Garcia-Martinez J, Castano A, De la Vieja A . From obesity to diabetes and cancer: epidemiological links and role of therapies. Br J Cancer. 2016; 114(7):716-22. PMC: 4984860. DOI: 10.1038/bjc.2016.37. View

3.
Yilmaz Y, Gunes A, Topel H, Atabey N . Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis. J Gastrointest Cancer. 2017; 48(3):225-237. DOI: 10.1007/s12029-017-9958-1. View

4.
Shaul Y, Freinkman E, Comb W, Cantor J, Tam W, Thiru P . Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell. 2014; 158(5):1094-1109. PMC: 4250222. DOI: 10.1016/j.cell.2014.07.032. View

5.
Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View